Welcome to our dedicated page for Cosciens Biopharma news (Ticker: CSCI), a resource for investors and traders seeking the latest updates and insights on Cosciens Biopharma stock.
Cosciens Biopharma (CSCI) provides investors and industry professionals with centralized access to its latest corporate developments through this official news hub. Our repository features verified press releases and regulatory filings, offering transparent insights into the company's progress across therapeutic research, diagnostic innovations, and cosmetic ingredient technologies.
Discover updates spanning clinical trial milestones, strategic partnerships, and regulatory submissions, alongside financial disclosures and manufacturing advancements. All content is sourced directly from CSCI's communications team to ensure accuracy and timeliness.
Key categories include announcements about proprietary extraction technology applications, R&D breakthroughs in disease detection systems, and commercial expansions within the biopharmaceutical sector. This resource eliminates the need to track multiple channels by aggregating essential updates in one professionally curated location.
Bookmark this page for streamlined monitoring of CSCI's operational developments and scientific achievements. For comprehensive understanding of the company's strategic direction, combine these updates with periodic review of official SEC filings and annual reports.
COSCIENS Biopharma (NASDAQ/TSX: CSCI) announced Q2 2025 financial results and strategic initiatives, including plans to voluntarily delist from Nasdaq while maintaining TSX listing. The company reported Q2 revenue of $2.7M, up 17% year-over-year, with a net loss of $2.4M.
Key developments include a 27% workforce reduction, appointment of a new CEO and reconstituted Board of Directors, and implementation of zero-based budgeting. The company ended Q2 with $9.3M in cash. Their pharmaceutical pipeline includes Macrilen, which missed primary endpoints in Phase 3 DETECT trial, and AvenActive, currently in Phase 2a testing.
The Nasdaq delisting, expected around September 4, 2025, aims to reduce costs and streamline operations, with plans to transition to OTC trading in the US while maintaining TSX listing.
COSCIENS Biopharma (NASDAQ: CSCI; TSX: CSCI), a life sciences company focused on cosmeceutical, nutraceutical and pharmaceutical products, has announced the results of its virtual annual general and special meeting of shareholders (AGSM).
All six directors were successfully elected to the board, with most nominees receiving over 88% approval, except for Ronald W. Miller who received 68.75% of votes in favor. The shareholders also approved the appointment of Deloitte LLP as the company's auditor and passed a resolution approving the Amended and Restated Shareholder Rights Plan.
As an Eligible Interlisted Issuer on the TSX, COSCIENS obtained an exemption from certain Canadian requirements regarding its long-term incentive plan, eliminating the need for shareholder approval of unallocated entitlements at the AGSM.
COSCIENS Biopharma (NASDAQ/TSX: CSCI), a life sciences company focused on cosmeceutical, nutraceutical and pharmaceutical products, has received a letter from Goodwood Fund and Puccetti Funds Management proposing six director nominations for the upcoming Annual and Special Meeting of Shareholders. Board Chair Ronnie Miller acknowledged receipt of the nominations and stated that the board will review the contents and determine next steps while maintaining commitment to shareholder interests.
COSCIENS Biopharma (NASDAQ: CSCI) has appointed Anna Biehn as Chief Executive Officer, effective May 5, 2025. Biehn brings over 25 years of experience in consumer products and biosciences industries, most recently serving as CFO of NuTek Natural Ingredients.
Current President and CEO Gilles Gagnon, who has been with the company since 2008, will transition to a Strategic Advisor and Director role. The leadership change comes as COSCIENS, a life science company developing cosmeceutical, nutraceutical and pharmaceutical products, aims to strengthen its position in natural-based products for health and wellness.
Biehn's previous experience includes serving as VP Strategy and Marketing at NuTek Natural Ingredients and President of Consumer Foods International at Conagra. She holds board positions at PretzelHaus Bakery and Baldwin Richardson Foods, and has an MBA from the University of Denver.
COSCIENS Biopharma (NASDAQ: CSCI) has reported its Q4 and full-year 2024 financial results, marking a transformative year with a strategic repositioning as a pure-play natural-based product company. The company achieved revenues of $9.6M in 2024, up 35.2% from $7.1M in 2023.
Key financial highlights include a cash position of $16.4M as of December 31, 2024, and a full-year net loss of $15.3M ($5.93 per share) compared to $3.5M loss in 2023. Operating expenses increased to $23.0M from $7.5M in 2023.
Development updates include successful Phase 1 results for Avenanthramides Tablets, launch of Phase 2a clinical study, and progress in cosmeceuticals and nutraceuticals. The company has halted investment in pre-clinical programs and macimorelin development following negative Phase 3 DETECT-Trial results. New product launches planned include OBG chewable bars and YBG immune booster products in H2 2025.
COSCIENS Biopharma (NASDAQ/TSX: CSCI) has received a Management Cease Trade Order (MCTO) from the Ontario Securities Commission effective April 1, 2025. The MCTO was issued due to potential delays in filing required annual financial documents for 2022-2024, including financial statements, management discussion, CEO/CFO certificates, and Form 20-F.
The company expects to complete these filings by April 7, 2025. The MCTO restricts the CEO and CFO from trading company securities until the required filings are completed. Regular shareholders unaffected by this order can continue trading normally.
While the MCTO won't immediately impact CSCI's Nasdaq Capital Market listing, the company must issue bi-weekly status updates until the situation is resolved. COSCIENS confirms no material changes since their March 19 default announcement.
COSCIENS Biopharma (NASDAQ/TSX: CSCI) announced potential delays in filing its annual financial statements, CEO/CFO certificates, and annual information form (Form 20-F) beyond the March 31, 2025 deadline. The delay stems from complications following the 2024 all-stock merger with Ceapro, requiring additional time for accounting procedure conversion and internal control review.
The company identified material weaknesses in financial controls as of December 31, 2024, with deficiencies in the COSO framework principles. Additional review is also needed regarding the impact of prospective U.S. tariffs.
As a precautionary measure, COSCIENS has applied for a management cease trade order (MCTO) with the Ontario Securities Commission. The company confirms this potential delay does not immediately affect its Nasdaq Capital Market listing and will issue bi-weekly status updates if an MCTO is granted.
COSCIENS Biopharma (NASDAQ/TSX: CSCI) announced potential delays in filing its annual financial statements, CEO/CFO certificates, and annual information form (Form 20-F) beyond the March 31, 2025 deadline. The delay stems from complications related to their 2024 all-stock merger with Ceapro, requiring accounting procedure conversions to meet SEC reporting obligations.
The company identified material weaknesses in financial controls as of December 31, 2024, with deficiencies in the COSO framework principles. Additional review is also needed regarding the impact of prospective U.S. tariffs. As a precautionary measure, COSCIENS has applied for a management cease trade order (MCTO) with the Ontario Securities Commission, though this won't affect non-management trading.
While the delay doesn't immediately impact CSCI's Nasdaq Capital Market listing, the company commits to issuing bi-weekly status updates and completing the required filings as soon as possible.
FAQ
What is the current stock price of Cosciens Biopharma (CSCI)?
What is the market cap of Cosciens Biopharma (CSCI)?
